首页> 外文期刊>Modern Pathology >EGFR and HER-2|[sol]|neu expression in invasive apocrine carcinoma of the breast
【24h】

EGFR and HER-2|[sol]|neu expression in invasive apocrine carcinoma of the breast

机译:EGFR和HER-2 | [sol] | neu在乳腺浸润性浸润癌中的表达

获取原文
       

摘要

This study was undertaken to investigate epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER-2)eu expression in a cohort of apocrine carcinomas of the breast with emphasis on the classification of the breast tumors with apocrine morphology. In total, 55 breast carcinomas morphologically diagnosed as apocrine were evaluated for the steroid receptor expression profile characteristic of normal apocrine epithelium (androgen receptor positive/estrogen receptor (ER) negative/progesterone receptor (PR) negative), and for the expression of EGFR and Her-2eu proteins, and the copy number ratios of the genes EGFR/CEP7 and HER-2/CEP17. On the basis of the results of steroid receptors expression, 38 (69%) cases were classified as pure apocrine carcinoma (androgen receptor positive/ER negative/PR negative), whereas 17 (31%) were re-classified as apocrine-like carcinomas because they did not have the characteristic steroid receptor expression profile. Her-2eu overexpression was observed in 54% of the cases (57% pure apocrine carcinomas vs 47% apocrine-like carcinomas). HER-2eu gene amplification was demonstrated in 52% of all cases (54% pure apocrine carcinomas vs 46% apocrine-like carcinomas). EGFR protein (scores 1 to 3+) was detected in 62% of all cases and was expressed in a higher proportion of pure apocrine carcinomas than in the apocrine-like carcinomas group (76 vs 29%, P=0.006). In the pure apocrine carcinoma group, Her-2eu and EGFR protein expression were inversely correlated (P=0.006, r=?0.499). EGFR gene amplification was observed in two pure apocrine carcinomas and one apocrine-like carcinoma. Polysomy 7 was commonly present in pure apocrine carcinomas (61 vs 27% of apocrine-like carcinomas; P=0.083) and showed a weak positive correlation with EGFR protein expression (P=0.025, r=0.326). Our study showed that apocrine breast carcinomas are molecularly diverse group of carcinomas. Strictly defined pure apocrine carcinomas are either HER-2-overexpressing breast carcinomas or triple-negative breast carcinomas, whereas apocrine-like carcinomas predominantly belong to the luminal phenotype. Pure apocrine carcinomas show consistent overexpression of either EGFR or HER-2eu, which could have significant therapeutic implications.
机译:这项研究旨在研究表皮生长因子受体(EGFR)和人表皮生长因子受体2(HER-2)/ neu在乳腺癌中的顶细胞癌队列中的表达,重点是按顶细胞形态对乳腺肿瘤的分类。总共评估了55例经形态学诊断为载脂蛋白的乳腺癌,以评估正常载脂蛋白上皮的类固醇受体表达谱特征(雄激素受体阳性/雌激素受体(ER)阴性/孕激素受体(PR)阴性),以及EGFR和Her-2 / neu蛋白,以及EGFR / CEP7和HER-2 / CEP17基因的拷贝数比。根据类固醇受体表达的结果,将38例(69 %)病例归为纯顶泌腺癌(雄激素受体阳性/ ER阴性/ PR阴性),而17例(31 %)被重新分类为阿朴分泌-像癌症一样,因为它们没有特征性的类固醇受体表达谱。在54%的病例中观察到了Her-2 / neu过表达(57%的纯顶泌癌相对于47%的阿朴样癌)。在所有病例中有52%证实了HER-2 / neu基因的扩增(54%的纯顶泌癌和46%的阿朴样癌)。在所有病例中检测到EGFR蛋白(得分1至3+),其表达水平高于纯阿朴类癌组(76对29%,P = 0.006)。在纯顶分泌癌组中,Her-2 / neu和EGFR蛋白表达呈负相关(P = 0.006,r =?0.499)。在两种纯顶泌癌和一种顶泌样癌中观察到EGFR基因扩增。多体性7通常存在于纯顶泌癌中(61%vs. 27%的顶泌样癌; P = 0.083),并且与EGFR蛋白表达呈弱正相关(P = 0.025,r = 0.326)。我们的研究表明,顶泌性乳腺癌是分子上各不相同的癌症组。严格定义的纯载脂蛋白癌是HER-2过表达的乳腺癌或三阴性乳腺癌,而载脂蛋白样癌则主要属于管腔表型。单纯的顶泌性癌表现出一致的EGFR或HER-2 / neu过表达,这可能具有重要的治疗意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号